Dr. Lisa Xingguang Lee, MD

Dr. Lee practices at City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD in Irvine, California.

Dr. Lee's NPI, 1144583733, was assigned on June 19, 2012. Dr. Lee graduated from Rutgers Robert Wood Johnson Medical School in 2012. Dr. Lee holds California license A156461.

Dr. Lee's primary practice is City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD, at 1000 Fivepoint, Irvine, CA 92618.

Dr. Lee's primary practice is City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD in Irvine, California. Dr. Lee is also affiliated with UCI Health - Orange. The medical group on file is City of Hope. Dmand AI also links Dr. Lee to 2 more group practices and clinics, 1 other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lee practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Lee's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Lee is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Lee's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists chronic anemia, chronic embolism thrombosis, chronic leukemia, deep vein thrombosis (DVT), lymphoma, multiple myeloma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Lee treats.

CMS data shows 794 Medicare services from Dr. Lee across 10 procedure codes in 2024, for 237 Medicare patients. Medicare paid $76,495 for them.

CMS counts 237 Medicare patients who saw Dr. Lee in 2024. The largest group is 65 to 74, with 99 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 2.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lee's median patient age at 68, with 54% women.

In 2024, Dr. Lee wrote 631 Medicare Part D claims for 65 patients. 72% of them were for generic drugs. CMS names the drug for 458 of them, across 18 drugs with 11 or more claims each, at $2,636,765 in total drug cost. In 2023, CMS named 382 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lee for performance year 2024, reported through an alternative payment model (APM). Dr. Lee accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lee as offering telehealth.

Dmand AI links 14 papers to Dr. Lee, published from 2017 to 2025. 2019 was the busiest year, with 2. The most frequent topics are Amyloidosis and Immunoglobulin Light-chain Amyloidosis. Dr. Lee has published most often in Clin Lymphoma Myeloma Leuk. Dr. Lee's most frequent co-authors are Raymond L. Comenzo, MD, Yen Thi Kim Hong Cao, MD and Minh-Ha Tran, DO.

CMS Open Payments shows 13 general payments to Dr. Lee from 9 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 87% of the total. Bristol-Myers Squibb Company paid the most, $4,671. It also lists 4 research payments totaling $2,310 from 2023 to 2025, naming 1 clinical trial.

Dr. Lee graduated from Rutgers Robert Wood Johnson Medical School in 2012.

Dr. Lee is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.